HTRA inhibitors
- Summary
- Novel Ahp-cyclodepsipeptide-based HTRA inhibitors for the treatment of macular degeneration (HTRA1) or cell death in reperfusion-ischemia (HTRA2).
- Technology Benefits
- First-in-class inhibitors for HTRA
Novel promising drug target for various indications
- Technology Application
- Ahp-cyclodepsipeptides constitute a novel class of HTRA inhibitors and are thus qualified to be further developed as “first-in-class” drugs for that target.
- Detailed Technology Description
- Ahp-cyclodepsipeptides represent a suitable scaffold for generating target-tailored inhibitors of serine proteases. They have developed a practical mixed solid- and solution-phase synthesis that allows the customized synthesis of Ahp-cyclodepsipeptides and thus tailored inhibitor synthesis.
- Type of Cooperation
- Licensing
- Application Date
- 14/05/2018 00:00:00
- Application No.
- WO2018EP62381 20180514
- Classes
- - international:
C07K7/06; C07K7/54
- cooperative:
C07K11/00; C12Q1/37; A61K38/00; G01N2500/04
- Others
- Patent application
- ID No.
- 4907
- Country/Region
- Germany
For more information, please click Here
